Pharmerging Market is estimated to be US$ 4426.72 billion by 2030 with a CAGR of 16.5% during the forecast period - By PMI
July 04, 2022 09:45 ET
|
PMI
Covina, July 04, 2022 (GLOBE NEWSWIRE) -- Particularly in the worldwide emerging economies, the Pharmerging industry is growing significantly. Some of the main drivers of this market's expansion are...
Peptide Therapeutics Market is estimated to be US$ 66.18 billion by 2030 with a CAGR of 6.10% during the forecast period - By PMI
July 04, 2022 09:43 ET
|
PMI
Covina, July 04, 2022 (GLOBE NEWSWIRE) -- The joining of two or more amino acid monomers via amide bonds forms peptides. The size of a peptide is what separates it from a protein. Peptides are...
Revolution Medicines Reports First Quarter 2022 Financial Results and Update on Corporate Progress
May 09, 2022 16:02 ET
|
Revolution Medicines, Inc.
Lead RAS(ON) Inhibitor drug candidates RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) approaching the clinic RMC-4630-03 Phase 2 trial evaluating RAS Companion Inhibitor RMC-4630 (SHP2) in combination...
Global Human Insulin Market is estimated to be US$ 35.01 Billion in 2030 at a CAGR 4.3% during the forecast period - By PMI
April 05, 2022 09:52 ET
|
PMI
Covina, April 05, 2022 (GLOBE NEWSWIRE) -- Global Human Insulin Market accounted for US$ 22.97 billion in 2020 and is estimated to be US$ 35.01 billion by 2030 and is anticipated to register a CAGR...
Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress
February 28, 2022 16:05 ET
|
Revolution Medicines, Inc.
RAS(ON) Inhibitor Pipeline Continues to Advance and Expand, Now Addressing Majority of RAS-Addicted Cancers; Two New Drug Candidates Recently Nominated Recently Announced First Patient Dosed in...
Sanofi's vaccine are the most administered pediatric vaccines in the world
February 10, 2022 05:59 ET
|
ReportLinker
Lyon, Feb. 10, 2022 (GLOBE NEWSWIRE) -- A new study shows that Sanofi Pasteur is the global leader in the aP-based pediatric combination vaccines market including hexavalent, pentavalent and school...
BrightInsight Announces Partnership with Sanofi to Bring to Market a Next Generation Digital Companion Application
January 10, 2022 08:30 ET
|
BrightInsight
SAN JOSE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today a...
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle
December 20, 2021 23:30 ET
|
Sanofi - Aventis Groupe
Sanofi va acquérir Amunix pour son portefeuille en immuno-oncologie avec une nouvelle génération d’agents biologiques à activation conditionnelle Une opération qui apporte un portefeuille...
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
December 20, 2021 23:30 ET
|
Sanofi - Aventis Groupe
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics Adds promising pipeline of T-cell engagers and cytokine therapies with lead candidate...
KADMON ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of KDMN and Encourages Investors to Contact the Firm
September 09, 2021 11:52 ET
|
Bragar Eagel & Squire
NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or...